LMAT icon

LeMaitre Vascular

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 45.5%
Negative

Positive
Zacks Investment Research
2 days ago
Here is Why Growth Investors Should Buy LeMaitre (LMAT) Now
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here is Why Growth Investors Should Buy LeMaitre (LMAT) Now
Positive
Zacks Investment Research
15 days ago
New Strong Buy Stocks for November 14th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
New Strong Buy Stocks for November 14th
Neutral
CNBC Television
16 days ago
Final Trade: LMAT, REGN, BA, TJX
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Final Trade: LMAT, REGN, BA, TJX
Neutral
GlobeNewsWire
17 days ago
LeMaitre to Participate in Upcoming Investor Conferences
BURLINGTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
LeMaitre to Participate in Upcoming Investor Conferences
Positive
Zacks Investment Research
18 days ago
3 Reasons Why Growth Investors Shouldn't Overlook LeMaitre (LMAT)
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Reasons Why Growth Investors Shouldn't Overlook LeMaitre (LMAT)
Neutral
Seeking Alpha
22 days ago
LeMaitre Vascular, Inc. (LMAT) Q3 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. ( LMAT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dorian LeBlanc - Chief Financial Officer George LeMaitre - Chairman & CEO David Roberts - President & Director Conference Call Participants Michael Sarcone - Jefferies LLC, Research Division Shaymus Contorno - Oppenheimer & Co. Inc., Research Division Rick Wise Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division James Sidoti - Sidoti & Company, LLC Kyle Bauser - ROTH Capital Partners, LLC, Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division Presentation Operator Hello. Good day. This is RJ, your conference operator today, and we welcome you to the LeMaitre Vascular, Inc. Q3 2025 Financial Results Conference Call.
LeMaitre Vascular, Inc. (LMAT) Q3 2025 Earnings Call Transcript
Positive
Zacks Investment Research
22 days ago
LeMaitre Vascular (LMAT) Q3 Earnings Surpass Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.49 per share a year ago.
LeMaitre Vascular (LMAT) Q3 Earnings Surpass Estimates
Neutral
GlobeNewsWire
23 days ago
LeMaitre Q3 2025 Financial Results
BURLINGTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance.
LeMaitre Q3 2025 Financial Results
Positive
Zacks Investment Research
1 month ago
PHG or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Royal Philips (PHG) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
PHG or LMAT: Which Is the Better Value Stock Right Now?
Neutral
GlobeNewsWire
1 month ago
LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
BURLINGTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after the market close.
LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025